Product image of Mezavant (Mesalazine) supplied by GNH India

Mezavant

Active Ingredient:
Mesalazine
Origin:
EU

Mezavant (Mesalazine)

Mesalazine, the active ingredient in Mezavant, is a 5‑aminosalicylic acid (5‑ASA) derivative presented as a delayed‑release tablet for oral use. It is indicated for the treatment of ulcerative colitis in adult patients, helping to reduce colonic inflammation and maintain remission.

GNH India supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across multiple continents. The company adheres to stringent quality standards and provides regulatory support for import and distribution. Clients benefit from reliable logistics, batch traceability, and on‑time delivery.

Manufacturer / TM Owner

Takeda Pharmaceuticals International Ag Ireland Branch

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mezavant (mesalazine) is employed to manage inflammatory conditions of the colon, chiefly ulcerative colitis.

  • Ulcerative colitis (induction): reduces active inflammation and induces remission in mild to moderate disease.
  • Ulcerative colitis (maintenance): helps maintain remission and prevent relapse over long‑term therapy.
  • Ulcerative proctitis: treats inflammation confined to the rectum, improving bowel habits and reducing bleeding.
  • Mild to moderate colonic inflammation: alleviates symptoms such as abdominal pain, urgency, and diarrhea.

How It Works

  • Mesalazine acts locally in the colon by inhibiting cyclooxygenase and lipoxygenase pathways, which reduces the synthesis of prostaglandins and leukotrienes. It also modulates cytokine release and interferes with nuclear factor‑κB signaling, leading to decreased inflammatory cell activation and attenuation of mucosal inflammation.

Side Effects

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects

  • Nausea: occasional feeling of stomach upset.
  • Abdominal pain: mild cramping or discomfort.
  • Headache: transient head pain.
  • Flatulence: increased intestinal gas.
  • Rash: mild skin irritation.
  • Altered taste: temporary change in flavor perception.

Serious or Rare Side Effects

  • Pancreatitis: inflammation of the pancreas requiring medical attention.
  • Severe allergic reaction: symptoms such as swelling, hives, or difficulty breathing.
  • Interstitial nephritis: kidney inflammation that may impair function.
  • Hepatotoxicity: liver enzyme elevations indicating possible liver injury.
  • Myocarditis: inflammation of heart muscle, a rare but serious condition.
  • Blood dyscrasias: abnormal blood counts including anemia or leukopenia.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Renal function monitoring: assess kidney function periodically, especially in patients with pre‑existing renal disease.
  • Hepatic function monitoring: check liver enzymes regularly to detect potential hepatotoxicity.
  • Disease severity assessment: ensure appropriate use in mild to moderate ulcerative colitis.
  • Hypersensitivity: avoid in patients with known allergy to mesalazine or related compounds.
  • Concomitant NSAIDs: use with caution as combined therapy may increase risk of renal impairment.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Mesalazine may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid)

  • Antacids containing magnesium or aluminum: may reduce mesalazine absorption and effectiveness.
  • NSAIDs: combined use can increase risk of renal impairment.
  • Warfarin: may enhance anticoagulant effect and raise bleeding risk.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor renal function and electrolytes.
  • ACE inhibitors: watch for additive effects on kidney function.
  • Lithium: monitor serum lithium levels for potential toxicity.

Frequently Asked Questions

Mezavant contains mesalazine, which is prescribed to treat ulcerative colitis. It helps reduce inflammation in the colon, alleviates symptoms such as diarrhea and bleeding, and can be used both to induce remission in active disease and to maintain remission over time.

Mesalazine acts locally in the colon by blocking enzymes that produce inflammatory mediators like prostaglandins and leukotrienes. It also modulates cytokine release and inhibits nuclear factor‑κB signaling, resulting in reduced recruitment of inflammatory cells and decreased mucosal inflammation.

The dosage of Mezavant is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Healthcare professionals determine the appropriate strength and frequency, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

Safety data for mesalazine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians weigh potential benefits against risks, and the drug should only be used if clearly needed. Breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the Mezavant product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant (mesalazine) belongs to the 5‑ASA class, which is often first‑line for mild to moderate ulcerative colitis. Compared with systemic steroids or immunomodulators, mesalazine offers a targeted, oral approach with a lower systemic side‑effect profile, though it may be less potent in severe disease.

Store Mezavant tablets at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mezavant is taken orally as a delayed‑release tablet. The tablet should be swallowed whole with water and not crushed, chewed, or split, to preserve the coating that releases the drug in the colon where it exerts its anti‑inflammatory effect.

Serious adverse reactions, though rare, include pancreatitis, severe allergic reactions such as anaphylaxis, interstitial nephritis, hepatotoxicity, myocarditis, and significant blood dyscrasias. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, jaundice, rash, or unexplained bruising.

Mezavant should be avoided in individuals with known hypersensitivity to mesalazine or any component of the tablet. Caution is also advised for patients with severe renal or hepatic impairment, and those taking medications that may interact significantly, such as certain NSAIDs or anticoagulants, unless closely monitored.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mesalazine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT